Searching Therapeutic Strategies of COVID-19 from Angiotensin-converting Enzyme 2：the Receptor of 2019-nCoV and SARS-CoV

doi:10.12114/j.issn.1007-9572.2020.00.251

Abstract

Abstract: The COVID-19 outbreak occurred in Wuhan，China，in December 2019 has aroused wide public concern.Both 2019-nCoV and SARS-CoV belong to the coronaviridae family，and invade target cells through ACE2.So an in-depth understanding of ACE2 and a series of pathophysiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical manifestations and then deal with them timely.In addition，ACE2 is a potential therapeutic target，according to this，we can find the corresponding treatment strategy.This article explains the role of ACE2 in multiple organ damage caused by 2019-nCoV and SARS-CoV，and blockers targeting ACE2，and inflammation inhibitors，with a view to providing a basis for subsequent related research，diagnosis and treatment，and drug development.

Key words: Coronavirus infections, 2019-nCoV, SARS-CoV, Angiotensin-converting enzyme 2

摘要： 自2019年12月以来，新型冠状病毒（2019-nCoV）感染在中国武汉引发了新型冠状病毒肺炎的爆发，并引起了公众的极大关注。2019-nCoV与SARS-CoV均属于冠状病毒科，均通过血管紧张素转化酶2（ACE2）侵入靶细胞。深入了解ACE2及病毒侵入人体后以其为中心引起的一系列病生理变化机制，可能有助于发现并解释相应的临床现象，进而及时予以处理；另外ACE2是潜在的治疗靶点，可以此寻找相应的救治策略。本文阐述了ACE2在2019-nCoV及SARS-CoV所致多脏器损伤中的作用、针对ACE2的靶向阻断药物以及抑制炎性反应的药物，旨在为后续相关研究及诊治、药物研发提供依据。

关键词: 冠状病毒感染, 新型冠状病毒, SARS冠状病毒, 血管紧张素转化酶2

TANG Zijian,LI Shuren,XU Wenhua, et al. Searching Therapeutic Strategies of COVID-19 from Angiotensin-converting Enzyme 2：the Receptor of 2019-nCoV and SARS-CoV　[J]. Chinese General Practice, 2020, 23(9): 1071-1077. DOI: 10.12114/j.issn.1007-9572.2020.00.251.
唐子健,李树仁,许文华等. 从2019-nCoV和SARS-CoV的侵袭靶点血管紧张素转化酶2寻找新型冠状病毒肺炎的救治策略[J]. 中国全科医学, 2020, 23(9): 1071-1077. DOI: 10.12114/j.issn.1007-9572.2020.00.251.

References

［1］中国疾病预防控制中心冠状病毒肺炎应急响应流行病学组.新型冠状病毒肺炎流行病学特征分析［J］．中华流行病学杂志，2020，41（2）：145-151．DOI：10.3760/cma.j.issn.0254-64502020.02.003.
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team.The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases（COVID-19） in China［J］．Chin J Epidemiol，2020，41（2）：145-151．DOI：10.3760/cma.j.issn.0254-64502020.02.003.
［2］DELANG，OSTERHAUS A D，HAAGMANS B L.Interferon-Gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells［J］．Virology，2006，353（2）：474-481．DOI：10.1016/j.virol.2006.06.011.
［3］XU X T，CHEN P，WANG J F，et al．Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission［J］．Sci China Life Sci，2020．［Epub ahead of print］．DOI：10.1007/s11427-020-1637-5.
［4］ZHOU P，YANG X L，WANG X G，et al．A pneumonia outbreak associated with a new coronavirus of probable bat origin［J］．Nature，2020．［Epub ahead of print］．DOI：10.1038/s41586-020-2012-7.
［5］DONOGHUE M，HSIEH F，BARONAS E，et al．A novel angiotensin-converting enzyme-related carboxypeptidase（ACE2） converts angiotensin I to angiotensin 1-9［J］．Circ Res，2000，87（5）：e1-9．DOI：10.1161/01.res.87.5.e1.
［6］OCARANZA M P，MICHEA L，CHIONG M，et al．Recent insights and therapeutic perspectives of angiotensin-（1-9） in the cardiovascular system［J］．Clin Sci，2014，127（9）：549-557．DOI：10.1042/CS20130449.
［7］WANG Y T，TIKELLIS C，THOMAS M C，et al．Angiotensin converting enzyme 2 and atherosclerosis［J］．Atherosclerosis，2013，226（1）：3-8．DOI：10.1016/j.atherosclerosis.2012.08.018.
［8］PRABAKARAN P，XIAO X D，DIMITROV D S.A model of the ACE2 structure and function as a SARS-CoV receptor［J］．Biochem Biophys Res Commun，2004，314（1）：235-241．DOI：10.1016/j.bbrc.2003.12.081.
［9］OUDIT G Y，KASSIRI Z，JIANG C，et al．SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS［J］．Eur J Clin Invest，2009，39（7）：618-625．DOI：10.1111/j.1365-2362.2009.02153.x.
［10］FERRARIO C M，MULLICK A E.Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease［J］．Pharmacol Res，2017，125（Pt A）：57-71．DOI：10.1016/j.phrs.2017.05.020.
［11］ANTONIAK S，CARDENAS J C，BUCZEK L J，et al．Protease-activated receptor 1 contributes to angiotensinⅡ-induced cardiovascular remodeling and inflammation［J］．Cardiology，2017，136（4）：258-268．DOI：10.1159/000452269.
［12］HUANG C L，WANG Y M，LI X W，et al．Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China［J］．Lancet，2020，395（10223）：497-506．DOI：10.1016/S0140-6736（20）30183-5.
［13］武汉金银潭医生前线手记：新型冠状病毒肺炎临床特征初探［EB/OL］．（2020-01-29）［2020-02-07］．http：//news.medlive.cn/all/info-news/show-165664_97.html.
［14］关于印发新型冠状病毒感染的肺炎诊疗方案（试行第五版）的通知［EB/OL］．（2020-02-05）［2020-02-07］．http：//www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
［15］CHEN N S，ZHOU M，DONG X，et al．Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan，China：a descriptive study［J］．Lancet，2020，395（10223）：507-513．DOI：10.1016/S0140-6736（20）30211-7.
［16］ZHAO Y，ZHAO Z，WANG Y，et al．Single-cell RNA expression profiling of ACE2，the putative receptor of Wuhan 2019-nCoV［J］．bioRxiv 2020．DOI：10.1101/2020.01.26.919985.https：//www.biorxiv.org/ content/10.1101/2020.01.26.919985v1.
［17］KUBA K，IMAI Y，RAO S，et al．A crucial role of angiotensin converting enzyme 2（ACE2） in SARS coronavirus-induced lung injury［J］．Nat Med，2005，11（8）：875-879．DOI：10.1038/nm1267.
［18］IMAI Y，KUBA K，RAO S，et al．Angiotensin-converting enzyme 2 protects from severe acute lung failure［J］．Nature，2005，436（7047）：112-116．DOI：10.1038/nature03712.
［19］张云海，宫丽崑，任进.血管紧张素转换酶2在SARS病理途径中的作用［J］．中国药理学与毒理学杂志，2007，21（1）：72-76．DOI：10.3867/j.issn.1000-3002.2007.01.014.
ZHANG Y H，GONG L K，REN J.Role of angiotensin converting enzyme 2 in pathogenesis of severe acute respiratory syndrome［J］．Chinese Journal of Pharmacology and Toxicology，2007，21（1）：72-76．DOI：10.3867/j.issn.1000-3002.2007.01.014.
［20］JIA H P.Pulmonary angiotensin-converting enzyme 2（ACE2） and inflammatory lung disease［J］．Shock，2016，46（3）：239-248．DOI：10.1097/SHK.0000000000000633.
［21］姚开涛，刘明瑜，李欣，等．中药连花清瘟治疗新型冠状病毒感染的肺炎回顾性临床分析［J］．中国实验方剂学杂志，2020．［Epub ahead of print］．DOI：10.13422/j.cnki.syfjx.20201099.
YAO K T，LIU M Y，LI X，et al．Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine Lianhua Qingwen［J］．Chinese Journal of Experimental Traditional Medical Formulae，2020．［Epub ahead of print］．DOI：10.13422/j.cnki.syfjx.20201099.
［22］HOLSHUE M L，DEBOLT C，LINDQUIST S，et al．First case of 2019 novel coronavirus in the United States［J］．N Engl J Med，2020．［Epub ahead of print］．DOI：10.1056/NEJMoa2001191.
［23］ZHANG H，KANG Z，GONG H，et al．The digestive system is a potential route of 2019-nCoV infection：a bioinformatics analysis based on single-cell transcriptomes［J］．bioRxiv 2020．DOI：10.1101/2020.01.30.927806.
［24］HASHIMOTO T，PERLOT T，REHMAN A，et al．ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation［J］．Nature，2012，487（7408）：477-481．DOI：10.1038/nature11228.
［25］KHAJAH M A，FATEEL M M，ANANTHALAKSHMI K V，et al．
Anti-inflammatory action of angiotensin 1-7 in experimental colitis［J］．PLoS One，2016，11（3）：e0150861．DOI：10.1371/journal.pone.0150861.
［26］LI Z，WU M，GUO J，et al．Caution on kidney dysfunctions of 2019-nCoV patients［J］．MedRxiv，2020．［Epub ahead of print］．DOI：10.1101/2020.02.08.20021212.
［27］FAN C，LI K，DING Y，et al．ACE2 Expression in kidney and testis may cause kidney and testis damage after 2019-nCoV Infection［J］．Med Rxiv，2020．［Epub ahead of print］．DOI：10.1101/2020.02.12.20022418.
［28］CHAI X，HU L，ZHANG Y，et al．Specific ACE2 Expression in cholangiocytes may cause liver damage after 2019-nCoV infection［J］．bioRxiv 2020．［Epub ahead of print］．DOI：10.1101/2020.02.03.931766.
［29］HAN D P，PENN-NICHOLSON A，CHO M W.Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor［J］．Virology，2006，350（1）：15-25．DOI：10.1016/j.virol.2006.01.029.
［30］HUENTELMAN M J，ZUBCEVIC J，HERNáNDEZ PRADA J A，et al．Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor［J］．Hypertension，2004，44（6）：903-906．DOI：10.1161/01.HYP.0000146120.29648.36.
［31］HENRY C，ZAIZAFOUN M，STOCK E，et al．Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia［J］．Proc（Bayl Univ Med Cent），2018，31（4）：419-423．DOI：10.1080/08998280.2018.1499293.
［32］FERRARIO C M，JESSUP J，CHAPPELL M C，et al．Effect of angiotensin-converting enzyme inhibition and angiotensinⅡ receptor blockers on cardiac angiotensin-converting enzyme 2［J］．Circulation，2005，111（20）：2605-2610．DOI：10.1161/CIRCULATIONAHA.104.510461.
［33］KHAN A，BENTHIN C，ZENO B，et al．A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome［J］．Crit Care，2017，21（1）：234．DOI：10.1186/s13054-017-1823-x.
［34］牛明，王睿林，王仲霞，等．基于临床经验和分子对接技术的抗新型冠状病毒中医组方快速筛选模式及应用［J］．中国中药杂志，2020．［Epub ahead of print］．DOI：10.19540/j.cnki.cjcmm.20200206.501.
NIU M，WANG R L，WANG Z X，et al，Rapid establishment of traditional Chinese medicine prevention and treatment for the novel coronavirus pneumonia based on clinical experience and molecular docking［J］．China Journal of Chinese Materia Medica，2020．［Epub ahead of print］．DOI：10.19540/j.cnki.cjcmm.20200206.501.
［35］屈高洁，廖玲，胡康.黄芪甲苷治疗急性呼吸衰竭模型大鼠的效果及作用机制研究［J］．实用医学杂志，2019，35（19）：3014-3017.
QU G J，LIAO L，HU K.Effect and mechanism of Astragaloside A on acute respiratory failure in rats［J］．The Journal of Practical Medicine，2019，35（19）：3014-3017.
［36］江一川.基于血管紧张素转化酶2的人参总皂苷多系统保护作用研究［D］．长春：吉林大学，2017.
［37］LEI C，FU W，QIAN K，et al．Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig［J］．bioRxiv，2020.［Epub ahead of print］．DOI：10.1101/2020.02.01.929976.
［38］澎湃新闻-北大团队：咳嗽水“沐舒坦”具治疗新冠肺炎病毒潜力［EB/OL］．（2020-01-29）［2020-02-07］．https：//www.thepaper.cn/newsDetail_forward_4141235.

[1]	HUANG Lihui, SHU Juan, TAO Huihui, BAO Hairong. Progress in Treatment of Post Inflammatory Pulmonary Fibrosis Induced by SARS-CoV-2 Infection [J]. Chinese General Practice, 2024, 27(32): 4085-4092.
[2]	YU Na, BAI Xiaoling, PANG Jin, NIU Yutian, HU Qing, WANG Yuanfang, YANG Rongze. The Experience of Inhaled COVID-19 Vaccination among First-line Medical Staff in Epidemic Prevention Aged≥18 Years in Guiyang City: a Qualitative Study [J]. Chinese General Practice, 2023, 26(36): 4575-4580.
[3]	Yu WU, Jue LIU, Min LIU, Wannian LIANG. Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5 [J]. Chinese General Practice, 2022, 25(30): 3721-3725.
[4]	Wendi JIANG, Jinjin WANG, Shanshan LI, Yang YANG, Shuai HAO, Zhihui TONG, Wenpeng CAI. Awareness and Skills of Correctly Donning and Doffing Personal Protective Equipment in SARS-CoV-2 Omicron Containment Workers from a Mobile Cabin Hospital [J]. Chinese General Practice, 2022, 25(30): 3726-3733.
[5]	Renfeng YU, Xiaocang ZOU, Dayang ZOU, Linhao LI, Kehui WANG, Xiaoming HE, Yaqing XU, Rihui QIN, Dongdong MO, Jiahui Duan, Tao YU, Wei LIU, Jinpeng GUO. Study of Fluorescence Immunochromatography Based on Quantum Dots for the Detection of SARS-CoV-2 anti-N Protein IgG Antibody [J]. Chinese General Practice, 2022, 25(14): 1741-1749.
[6]	WU Yu, LIU Min. The Incubation Period of COVID-19 Caused by Different SARS-CoV-2 Variants [J]. Chinese General Practice, 2022, 25(11): 1309-1313.
[7]	WU Yu, LIU Jue, LIU Min, LIANG Wannian. Epidemiologic Features and Containment of SARS-CoV-2 Omicron Variant [J]. Chinese General Practice, 2022, 25(01): 14-19.
[8]	LIU Qiao，LIU Jue，LIU Min. Role and Containment of Asymptomatic Cases in COVID-19 Transmission　 [J]. Chinese General Practice, 2021, 24(8): 917-922.
[9]	DING Jianwen，LIU Baohou. Strategies of TCM Syndrome Differentiation to Encounter Asymptomatic Cases Infected with Coronavirus，Even if without Symptoms Macrocosmically　 [J]. Chinese General Practice, 2021, 24(3): 259-266.
[10]	DAI Juhua，LIN Bozhi，SUN Xinping. Exploration on the Detection Results of 2019 Novel Coronavirus Antibodies in the Real World　 [J]. Chinese General Practice, 2021, 24(26): 3338-3342.
[11]	Leon Piterman. Thinking，Judgement and Decision Making in the Prevention and Control of COVID-19 Leon Piterman [J]. Chinese General Practice, 2021, 24(25): 3171-3174.
[12]	LUO Fei，LI Shuren，HAO Xiao，BAI Yuhao，YUAN Kexin，XIE Yuetao. Recent Developments in the Pathogenesis of COVID-19-associated Myocarditis　 [J]. Chinese General Practice, 2021, 24(20): 2589-2593.
[13]	CAI Miaotian，LI Tongzeng，ZHANG Longyu，XU Hui，MOU Danlei，LIANG Lianchun. Clinical Features and Prognostic Risk Factors of COVID-19 in Adults: a Retrospective Analysis of 93 Cases　 [J]. Chinese General Practice, 2021, 24(2): 196-204.
[14]	LIU Jue，LIANG Wannian，LIU Min，YANG Weizhong，LIU Xia，WU Jing，WANG Yadong，SHAN Guangliang，HAN Hui，ZHOU Lei. Development of the COVID-19 Cluster Containment Evaluation System Using the Emergency Management Theory　 [J]. Chinese General Practice, 2021, 24(17): 2122-2126.
[15]	ZU Ming，SHI Yanyan，NING Jing，LU Haoping，ZHAO Zhiling，CHENG Qin，SHEN Ning，GE Qinggang，DING Shigang. Clinical Characteristics，Severity of Illness and Its Influencing Factors in COVID-19 Patients with Diarrhea as the Initial Symptom　 [J]. Chinese General Practice, 2021, 24(15): 1874-1882.